| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 9/14/2023, p1424-1424, 1p |
| Abstrakt: |
The novel antagonizing antibody 22E6 and therapeutic antibody Cetuximab served as inhibitors of CD73 and EGFR, respectively, in combinatorial treatment. Keywords: Antibodies; Antineoplastic Monoclonal Antibodies; Antineoplastics; Biomarkers; Biotechnology; Blood Proteins; Cancer; Carcinomas; Cetuximab Therapy; Diagnostics and Screening; Drugs and Therapies; EGFR Inhibitors; Epidermal Growth Factor Receptor; Epidermal Growth Factors; Gastrointestinal Hormone Receptors; Gastrointestinal Hormones; Growth Factor Receptors; Head and Neck Cancer; Health and Medicine; Human Papillomavirus; Immunoglobulins; Immunologic Agents; Immunology; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Monoclonal Antibodies; Oncology; Pharmaceuticals; Phosphotransferases; Protein Kinases; Proteins; Receptor Protein-Tyrosine Kinases; Tyrosine Kinase Inhibitors EN Antibodies Antineoplastic Monoclonal Antibodies Antineoplastics Biomarkers Biotechnology Blood Proteins Cancer Carcinomas Cetuximab Therapy Diagnostics and Screening Drugs and Therapies EGFR Inhibitors Epidermal Growth Factor Receptor Epidermal Growth Factors Gastrointestinal Hormone Receptors Gastrointestinal Hormones Growth Factor Receptors Head and Neck Cancer Health and Medicine Human Papillomavirus Immunoglobulins Immunologic Agents Immunology Intercellular Signaling Peptides and Proteins Membrane Proteins Monoclonal Antibodies Oncology Pharmaceuticals Phosphotransferases Protein Kinases Proteins Receptor Protein-Tyrosine Kinases Tyrosine Kinase Inhibitors 1424 1424 1 09/11/23 20230914 NES 230914 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on head and neck cancer. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
